Kelun Biotech

Pre-IPO Kelun Biotech (PHIP Updates) - Some Points Worth the Attention

576 Views07 Jun 2023 08:55
We're not optimistic about the future commercialization of A166/SKB264. As a company without sustainable growth capability, traditional financial model doesn't work. We shared our views on valuation.
Boomeranged on Wed, 12 Jul 2023 09:25
Currently, Kelun-Biotech's market value has already been higher than that of Keymed. Considering Keymed has complete R&D team within the company, strong license-out deal with AZ, as well as NDA stage big variety CM310, we think its market value could be surpass Kelun-Biotech in the future. Thus, we recommend investors to be rational when trading Kelun-biotech.
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
(Paid Plans Only)